Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intismeran Autogene + Pembrolizumab + Chemotherapy in Metastatic Squamous NSCLC
NCT07221474Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Jul 2029
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 11
01
Overview
A Phase 2 trial of intismeran autogene in squamous cell carcinoma of the lung (SCCL), sponsored by Merck & Co.. Started Dec 2025; status: recruiting.
02
Drugs
intismeran autogene
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07221474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221474.